According to the present invention, drug is manufactured using nanoliposome, the leading portion for preventing or treating eye disease provides. Nano liposomes include forming at least one in multiple unsaturated and/or saturation lipid encapsulated hydrophobic lipid bilayer to include tacrolimus, and in hydrophobic drug, multiple unsaturated and/or saturation lipid weight ratios are up to 0.2. The prevention and/or treatment that the present invention also provides such nano liposomes and method leading portion eye disease are based on nanoliposome.
